Member Info for David1951c

It seems as if the change in distribution is the reason for the significant SP drop then perhaps the major shareholders sitting on a huge value drop might see the better way forward is to restore the previous dividend policy. Such a u turn would make sense.

The fact that several potential investment partners have signed NDAs means that BRES should be able to strike a good deal and avoid discounted dilution. I am sure the Board will work very hard on this.

It is important too to crack on with P1 as this would put BRES at the front of the pack of aspiring producers. If P1 funding is completed quickly the off take side becomes more attractive and will be a potential win win for moving quickly on to P2.

I agree the lack of news is causing apathy and a few investors to look elsewhere for companies with a more encouraging outlook. I have a sizeable holding built up over 5+ years and I am disappointed that there have been few new contracts announced in 2026 after the bullish statments towards the end of last year. Investors with funds here may feel they are missing out on other opportunities. There seem to be a lot of loyal supporters here and knowingly take the risk of further disappointment.

Significant news could come at any time and the prospects remain very good especially if Unilever go ahead with new products using Apta.

Disappointing that the news on NCI is not more positive in terms of reaching an agreement and fees for ongoing and future use. A fee north of $2m pa would cover FAB's cost base and more would be great. FAB previously said negotiations could take months - OK but where are they with that now?

The important point for me is that fund raises are completed without significant SP discount. Last year it was 9%. Some fund raises are at much bigger discounts. The slight concern is another fund raise will probably be needed in 6 months or so unless the revenue increases very substantially. Hopefully the take up will accelerate and fund / support the developments with FDA.

NHS roll out is a victim of their funding constraints. They probably can see there are significant patient care advantages and later savings but the initial costs of a wider roll out inhibit the decision to go ahead.

There are various countries on the cusp of wider usage and importantly OBI are getting ready for expansion with their own in house capacity being increased. 2026 should be the pivotal year.

Hope so but the lack of news is a concern. I have quite a lot of shares (for me) and no news is not good news after 4 months of 2026 as far as I am concerned.

It seems very doubtful AMS board would accept a bid that low. The fact it is under discussion suggests a higher figure seems more likely. Anyway I doubt it will take long one way or the other.

According to AI, as of April 20 2026, Advanced Medical Solutions (AMS) is in advanced talks with TA Associates regarding a potential acquisition bid valuing the company at approximately £600 million, or roughly 280 pence per share.

How much is the offer?

An important factor for BRES is the timescale to production, which should be a lot shorter than SVML. Alligning phase 1 and 2 more closely with the much increased JORC would give a clear advantage and attractive to off takers. No doubt the Board will be working quickly to get first mover advantage.

MfG

Lots of helpful postes - much appreciated. To obtain the proposed banking licence requries sufficient capital reserves. Have you a view on what level this would be?

MBO looks an exciting opportunity with great potential but there are possible hurdles to meet on this point. I have invested and aim to buy more subjest to a fuller understanding.

Gtc

Revenues in Allenby's work probably do not include much for NCI which should be a big catalyst as well as the endorsement that others will take note of. Surely if SP is to rise significantly, then more revenue would be required that they estimate.

Not done the calculation yet but it hurts long term investors yet again. They are delighted witht the fund raise but no sympathy or understanding for the supporters over the years without which they might have struggled even more. They do what they can get away with which is pretty much anything. No such thing as rewarding loyalty.

Been in this for more than five years. I will probably buy more at the next fund raise.

Serica 2026 guidance is over 40k boepd and Mcap £1000m. Kistos 2026 guidance 20k boepd and Mcap £210m. Kistos undervalued IF Oman completes. Serica pay a good dividend.

I hadn't seen the second RNS when I posted earlier. Looks mainly good news so why do a fund raise? Suggests that developments like Unilever will take a lot longer to materialise if at all. What annoys me is that in being delighted with the fund raise, the placing price stitches up a lot of existing shareholders who have supported the company over the years. Long term loyalty counts for very little in this it seems.

Very disappointing but at least the discount is not massive albeit from a much reduced current SP. Fully agree the government support via the British Business Bank for small biotechs with greatr potential, is nothing short of abyssmal. The good news is the funds will speed up the many development threads and this is more likely to make the company a success.

I do feel Apta have been somewaht misleading in their statements on cash runway which gave the impression that no raises would be needed this year but one has happened in Q1. Also the chairman has been too bullish saying a lot of work was in hand just before Christmas but there have been few concrete new contracts. Also I am concerned about lack of news on Unilever collaboration - bad news travels slowly on company announcements.

I still feel that at some stage there will be a take over bid but in the meantime I just have to accept the disappointment but haven't yet worked out the dilution in share numbers with this raise. I no longer have 1% of the company.

If the situation was normal then Kistos seems hugely undervalued compared with other London listed mid size O&G companies. There is a war going on nearby and although the agreement to buy the assets is binding there is almost certainly get out conditions such as war. We are awaiting confirmation that the deal has been completed and this should happen (or not) in the next week or two. There is also a risk at Mina al Fahal but hopefully far enough away to keep the risk low.

The 2025 FY financials are also due soon and may depend on completion of the deal - could be a delay? Numbers could look really good if Oman is included. Cash would enable further expansion.

I have been in Kistos for a while after success in Rockrose and added again today but holding back due to uncertainties. I guess others are in the same boat.

Hopefully the resource update will be out this month which is a key for THX. An extension would mean two producing mines in 2028 and also support the funding of Douta. I am sure the company will use the best arrangements for financing also bearing in mind taxation and what is allowed by the mining conventions.

Good posts from NQM. Exports from Oman should not be materially affected as not passing through Hormuz Strait. Kistos should benefit from higher prices with Oman acquisition effective 1.1.2025 but let's all hope the conflict does not escalate or be prolonged.

FY 2025 results due in April should be very good as should Q1 this year.